Algert Global LLC Editas Medicine, Inc. Transaction History

Algert Global LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$7.03 - $11.07 $383,205 - $603,425	54,510 New	54,510 $404,000
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $15,484 - $33,092	-1,550 Reduced 13.1%	10,285 $122,000
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $166,636 - $327,001	11,835 New	11,835 $225,000
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $145,042 - $221,633	-5,463 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $214,532 - $398,471	5,463 New	5,463 $224,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $92.1M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.